Tipelukast is under clinical development by MediciNova and currently in Phase II for Type 2 Diabetes. According to GlobalData, Phase II drugs for Type 2 Diabetes have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tipelukast’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tipelukast overview
Tipelukast (KCA-757) is under development for the treatment of non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, idiopathic pulmonary fibrosis (IPF) and metabolic syndrome. It is administered orally in the form of tablet. The drug candidate targets leukotriene (LT) receptor, phosphodiesterases 3, 4, phospholipase C, 5-lipoxygenase and thromboxane A2. It was also under development for the treatment of bronchial asthma and interstitial cystitis.
MediciNova overview
MediciNova is a biopharmaceutical company that focuses on acquiring, and developing novel, small-molecule therapeutics for the treatment of neurological, respiratory, and liver diseases. MediciNova’s developmental pipeline includes core programs for the treatment of fibrotic diseases; neurological disorders; and respiratory diseases. The company’s non-core programs formulations developed for indications include treatment of bronchial asthma; interstitial cystitis; solid tumors; and for the treatment of preterm labor. It has partnerships with various companies such as Angiogene Pharmaceuticals Ltd, Kyorin Pharmaceutical Co Ltd, Kissei Pharmaceutical Co Ltd and Meiji Seika Kaisha Ltd, to develop and commercialize its products. The company is headquartered in La Jolla, California, the US.
For a complete picture of Tipelukast’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
